Naoki Shingai

Dr. Naoki Shingai


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YKYuya Kishida
Yuya Kishida
NSNaoki Shingai
Naoki Shingai
KHKonan Hara
Konan Hara
MYMakiko Yomota
Makiko Yomota
CKChika Kato
Chika Kato
NDNoriko Doki
Noriko Doki
Late-onset noninfectious pulmonary complications (LONIPC) are a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). However, the clinical impact of lung function deterioration itself in long-term adult survivors of HSCT remains to be fully investigated. This retrospective, longitudinal study aimed to investigate pulmonary function following HSCT in terms of its change and the clinical significance of its decline. We examined 167 patients who survived for at least 2 years without relapse. The median follow-up period was 10.3 years. A linear mixed-effects model showed that the slope of pulmonary function tests values, including percent vital capacity (%VC), percent forced expiratory volume in one second (%FEV1), and FEV1/forced VC ratio (FEV1%), decreased over time. The cumulative incidence of newly obstructive and restrictive lung function impairment (LFI) at 10 years was 15.7% and 19.5%, respectively. Restrictive LFI was a significant, independent risk factor for overall survival (hazard ratio 7.11, P = 0.007) and non-relapse mortality (hazard ratio 12.19, P = 0.003). Our data demonstrated that lung function declined over time after HSCT and that the decline itself had a significant impact on survival regardless of LONIPC.

23 May 2024 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
SKSatoshi Kaito
Satoshi Kaito
YNYuho Najima
Yuho Najima
DSDaichi Sadato
Daichi Sadato
CHChizuko Hirama
Chizuko Hirama
YKYuya Kishida
Yuya Kishida
NDNoriko Doki
Noriko Doki

20 May 2025 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
SKShuhei Kurosawa
Shuhei Kurosawa
KKKairi Kojo
Kairi Kojo
RYRiki Yamakawa
Riki Yamakawa
KKKana Kato
Kana Kato
YSYasutaka Sadaga
Yasutaka Sadaga
NDNoriko Doki
Noriko Doki

18 February 2023 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
MSMasahiro Sakaguchi
Masahiro Sakaguchi
YAYuya Atsuta
Yuya Atsuta
NSNoritaka Sekiya
Noritaka Sekiya
YNYuho Najima
Yuho Najima
KFKazuaki Fukushima
Kazuaki Fukushima
NDNoriko Doki
Noriko Doki
Although antipseudomonal agents are administered in high-risk patients, no reports have focused on the risk of carbapenem-resistant (CR) Pseudomonas aeruginosa bacteraemia in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. We retrospectively studied a cohort of adult allo-HSCT recipients with P. aeruginosa bacteraemia, focusing on a comparison between carbapenem-sensitive (CS) and CR P. aeruginosa after initiating conditioning chemotherapy at our institute between January 2005 and December 2020. The incidence, all-cause 30-d mortality of P. aeruginosa bacteraemia, and risk factors for carbapenem resistance among patients with P. aeruginosa bacteraemia in allo-HSCT recipients were evaluated. Forty-eight patients with P. aeruginosa bacteraemia were included, with an incidence of 3.84/100 recipients (CS = 1.92 vs. CR = 1.92). The all-cause 30-d mortality was significantly higher in CR P. aeruginosa bacteraemia (CS = 4.2% vs. CR = 39.1%; P = 0.003). The factor significantly associated with CR P. aeruginosa bacteraemia was carbapenem use for at least 3 d within 30 d before the onset of bacteraemia (odds ratio = 8.92; 95% confidence interval: 1.35-58.90). Inappropriate antimicrobial selection was significantly more frequent in CR P. aeruginosa bacteraemia (CS = 0% vs. CR = 29.2%; P ˂ 0.009). Empirical combination therapy with reference to antimicrobial susceptibility profiles in each institution should be considered when CR P. aeruginosa bacteraemia is suspected in allo-HSCT recipients based on the risk of carbapenem exposure.

24 April 2025 in Leukemia Research
Verified
Journal Article
Closed access
KKKaori Kondo
Kaori Kondo
YNYuho Najima
Yuho Najima
DSDaichi Sadato
Daichi Sadato
CHChizuko Hirama
Chizuko Hirama
KKKana Kato
Kana Kato
NDNoriko Doki
Noriko Doki

7 February 2024 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
YKYachiyo Kuwatsuka
Yachiyo Kuwatsuka
RKRika Kasajima
Rika Kasajima
RYRui Yamaguchi
Rui Yamaguchi
NUNaoyuki Uchida
Naoyuki Uchida
TKTakaaki Konuma
Takaaki Konuma
STSatoshi Takahashi
Satoshi Takahashi
Delayed neutrophil recovery is an important limitation to the administration of cord blood transplantation (CBT) and leaves the recipient vulnerable to life-threatening infection and increases the risk of other complications. A predictive model for neutrophil recovery after single-unit CBT was developed by using a machine learning method, which can handle large and complex datasets, allowing for the analysis of massive amounts of information to uncover patterns and make accurate predictions. Japanese registry data, the largest real-world dataset of CBT, was selected as the data source. Ninety-eight variables with observed values for more than 80% of the subjects known at the time of CBT were selected. Model building was performed with a competing risk regression model with lasso penalty. Prediction accuracy of the models was evaluated by calculating area under curve (AUC) using a test dataset. The primary outcome was neutrophil recovery at day 28 (D28), and D14 and D42 were analyzed as secondary outcomes. The final cord blood engraftment prediction (CBEP) models included 2,991 single-unit CBT recipients with acute leukemia. Median AUC of a D28-CBEP lasso regression model run 100 times was 0.74, and those of D14 and D42 were 0.88 and 0.68, respectively. The D28-CBEP model predictivity was higher than four different legacy models that were separately constructed. A highly predictive model for neutrophil recovery by 28 days after CBT was constructed using machine learning techniques. However, identification of significant risk factors was insufficient for outcome prediction for an individual patient, which is necessary for improving therapeutic outcomes. Notably, the prediction accuracy for days 14, 28, and 42 post-transplant decreased, and the model became more complex with more associated factors with increased time after transplantation.